Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Bank stocks drag indices lower
Tue, 17 May Closing

Disappointing set of numbers from banking behemoth SBI led the banking stocks to fall like a pack of cards and dragged the indices in the Indian stock market deep into the negative territory today. While the BSE-Sensex lost in the region of around 208 points (down 1.1%), the NSE-Nifty ended lower by around 60 points (down 1.1%). The BSE Midcap and BSE Small cap indices however, fared slightly better, both closing lower by around 0.6% each.

Most Asian indices closed the day mixed, with India featuring as the top loser in the region. Europe too is trading in the red currently. The rupee was trading at Rs 45.06 to the dollar at the time of writing.

SBI, the largest bank in the country today announced its fourth quarter and full year results for the financial year 2010-11 (FY11). The bank saw its net interest income grow by 15% YoY in FY11, on the back of 20% YoY growth in advances. Its NIMs (net interest margins) also moved up from 2.7% in FY10 to 3.3% in FY11 on lower cost of deposits. Profits were however, an altogether different story. The bank's net profit fell by 10% YoY in FY11, and by 99% YoY in 4QFY11 as provisions on advances and higher tax outlay ate into profits.

The bank had to make an extra Rs 5 bn provision on standard assets for its teaser-rate home loan schemes in accordance with the RBI's guidelines. The retail loan segment, of which home loans was a major contributor, was a huge growth driver for the bank over the past year. With the scheme coming to a close, and with the RBI's recent bout of rate hikes, the bank's growth prospects in this segment may be affected. SBI's capital adequacy ratio stood at 11.98% at the end of FY11 as per Basel II, indicating the need for a further capital infusion. However, with its right issue now being postponed, the only plausible course of action would be for the bank to temper its growth aspirations. The stock closed close to 8% lower for the day.

Aurobindo Pharma recently got approval for its generic drugs, Risperidone and Alendronate tablets from Australia's Therapeutic Goods Administration (TAG). These drugs are used to treat schizophrenia and osteoporosis, respectively. According to IMS, the market size of Risperdione is about US$ 27.5 m and that of Alendronate is US$ 14 m as of September, 2010. The stock however closed almost 2% lower in a weak market.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Bank stocks drag indices lower". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.